Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
27.66B
Market cap27.66B
Price-Earnings ratio
-29.60
Price-Earnings ratio-29.60
Dividend yield
Dividend yield
Average volume
1.69M
Average volume1.69M
High today
$126.92
High today$126.92
Low today
$121.11
Low today$121.11
Open price
$121.11
Open price$121.11
Volume
2.00M
Volume2.00M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$90.39
52 Week low$90.39

Stock Snapshot

Insmed Incorporated(INSM) stock is priced at $126.92, giving the company a market capitalization of 27.66B. It carries a P/E multiple of -29.60.

As of 2026-09-02, Insmed Incorporated(INSM) stock has fluctuated between $121.11 and $126.92. The current price stands at $126.92, placing the stock +4.8% above today's low and 0.0% off the high.

Insmed Incorporated(INSM) shares are trading with a volume of 2M, against a daily average of 1.69M.

During the past year, Insmed Incorporated(INSM) stock moved between $90.39 at its lowest and $212.75 at its peak.

During the past year, Insmed Incorporated(INSM) stock moved between $90.39 at its lowest and $212.75 at its peak.

INSM News

Simply Wall St 13h
Should Japan’s First Dedicated NCFB Approval for BRINSUPRI Reshape the Insmed Investment Debate? - simplywall.st

...

Should Japan’s First Dedicated NCFB Approval for BRINSUPRI Reshape the Insmed Investment Debate? - simplywall.st
Simply Wall St 2d
Is Insmed Undervalued Following Japan Approval For BRINSUPRI?

Advertisement Japan approval puts BRINSUPRI in all three major Insmed markets Insmed (INSM) has received approval from Japan's Ministry of Health, Labour and...

Is Insmed Undervalued Following Japan Approval For BRINSUPRI?
Simply Wall St 5d
Can Insmed Stay Reasonable After Its Japan Approval?

Insmed stock has delivered a very large gain over the past three years, yet current valuation checks lean toward the shares being priced on the expensive side r...

Can Insmed Stay Reasonable After Its Japan Approval?

Analyst ratings

100%

of 25 ratings
Buy
100%
Hold
0%
Sell
0%

More INSM News

Nasdaq 6d
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

Liquidia Corporation LQDA and Insmed INSM are both commercial-stage biopharmaceutical companies with a focus on developing innovative treatments for serious dis...

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.